Over time, we saw what happened next. We saw where patients dropped out. Where sites struggled. Where referrals stalled. Where technology helped — and where a nurse conversation made the difference. We learned what made patients respond, what helped sites convert, and what ultimately moved studies toward randomization.
There are very few enrollment challenges CTM has not encountered somewhere, on some study, with some patient population, or site. That experience matters because our clients do not have to start from zero.
What we have learned across more than 3,500+ studies and 6,300+ sites informs how we plan the next study. It is embedded in our technology. It shapes how we design screeners, engage patients, and support sites. And it powers RandIQ™, our predictive enrollment solution, so experience from the past can continually inform what happens next.
StudyMax™ did not begin as a generic technology platform adapted to clinical trials. It grew out of the enrollment work itself. It began with the need to find challenging patient populations due to complex protocol criteria, driving the need for better quality enrollment.
30 years of experience does not make CTM set in its ways. It gives us more to build from.
Every patient interaction, site experience, and study outcome adds to what we know. That learning goes back into our technology, our processes, and the way we approach the next enrollment challenge.
So while CTM today looks very different from the company that began in 1995, the principle behind it has never changed:
